Guardant Health - GH Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.

13 brokerages have issued 12 month price objectives for Guardant Health's stock. Their GH share price forecasts range from $65.00 to $165.00. On average, they predict the company's share price to reach $115.75 in the next year. This suggests a possible upside of 115.0% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.

Guardant Health's stock was trading at $100.02 at the beginning of the year. Since then, GH shares have decreased by 46.2% and is now trading at $53.83.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GH earnings forecast.

Guardant Health, Inc. (NASDAQ:GH) issued its quarterly earnings results on Thursday, August, 4th. The company reported ($2.25) earnings per share for the quarter, missing the consensus estimate of ($1.25) by $1.00. The business had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. Guardant Health had a negative trailing twelve-month return on equity of 99.90% and a negative net margin of 135.03%. The business's revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.96) earnings per share.

Guardant Health updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.29 million.

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $53.83.

Guardant Health (NASDAQ:GH) has a market capitalization of $5.50 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis.

The company employs 1,373 workers across the globe.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.